
Europe’s drug regulator is investigating the risk of suicidal thoughts and thoughts of self-harm in patients using some weight loss and diabetes jabs.
The European Medicines Agency’s (EMA) safety committee said it is looking at cases among people who use a semaglutide or liraglutide-containing medicine for weight loss.